AAAAAA

   
Results: 1-7 |
Results: 7
Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients
Authors: Obiezu, CV Scorilas, A Katsaros, D Massobio, M Yousef, GM Fracchioli, S de la Longrais, IAR Arisio, R Diamandis, EP
Citation: Cv. Obiezu et al., Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients, CLIN CANC R, 7(8), 2001, pp. 2380-2386
Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast
Authors: Sapino, A Bongiovanni, M Cassoni, P Righi, L Arisio, R Deaglio, S Malavasi, F
Citation: A. Sapino et al., Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast, J PATHOLOGY, 194(2), 2001, pp. 254-261
Evidence for a dose-response effect between p53 (but not p21(WAF1/Cip1)) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy
Authors: Levesque, MA Katsaros, D Massobrio, M Genta, F Yu, H Richiardi, G Fracchioli, S Durando, A Arisio, R Diamandis, EP
Citation: Ma. Levesque et al., Evidence for a dose-response effect between p53 (but not p21(WAF1/Cip1)) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy, CLIN CANC R, 6(8), 2000, pp. 3260-3270
Mammographically detected in situ lobular carcinomas of the breast
Authors: Sapino, A Frigerio, A Peterse, JL Arisio, R Coluccia, C Bussolati, G
Citation: A. Sapino et al., Mammographically detected in situ lobular carcinomas of the breast, VIRCHOWS AR, 436(5), 2000, pp. 421-430
What modifies the relation between tumour size and lymph node metastases in T1 breast carcinomas?
Authors: Arisio, R Sapino, A Cassoni, P Accinelli, G Cuccorese, MC Mano, MP Bussolati, G
Citation: R. Arisio et al., What modifies the relation between tumour size and lymph node metastases in T1 breast carcinomas?, J CLIN PATH, 53(11), 2000, pp. 846-850
Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma
Authors: Arts, HJG Katsaros, D de Vries, EGE Massobrio, M Genta, F Danese, S Arisio, R Scheper, RJ Kool, M Scheffer, GL Willemse, PHB van der Zee, AGJ Suurmeijer, AJH
Citation: Hjg. Arts et al., Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma, CLIN CANC R, 5(10), 1999, pp. 2798-2805
Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma
Authors: Lianidou, ES Levesque, MA Katsaros, D Angelopoulov, K Yu, H Genta, F Arisio, R Massobrio, M Bharaj, B Diamandis, EP
Citation: Es. Lianidou et al., Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma, ANTICANC R, 19(1B), 1999, pp. 749-756
Risultati: 1-7 |